AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca’s latest clinical study, titled A Phase I, Open-label Study to Assess the Absolute Bioavailability of Saruparib (AZD5305) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Saruparib ([14C]-AZD5305) in Patients With Advanced Solid Malignancies, aims to evaluate the bioavailability and pharmacokinetics of Saruparib in patients with advanced solid tumors. This study is significant as it explores the drug’s potential effectiveness and safety, contributing to the development of new cancer therapies.
The intervention being tested is Saruparib (AZD5305), a PARP inhibitor, along with its radiolabeled forms [14C]-AZD5305 microtracer and [14C]-AZD5305 (therapeutic dose). These drugs are intended to assess the absorption, distribution, metabolism, and excretion in patients, providing insights into the drug’s behavior in the human body.
This Phase I study is interventional with a non-randomized, single-group assignment. There is no masking involved, meaning all participants and researchers know which treatment is being administered. The primary purpose is basic science, focusing on understanding the drug’s pharmacokinetics and bioavailability.
The study began on April 2, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on August 18, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.
For AstraZeneca, this study could impact its stock performance positively if the results are favorable, as it would enhance the company’s oncology portfolio. Investor sentiment might also be influenced by the competitive landscape, where advancements in cancer treatment are highly valued.
The study is ongoing, and further details are available on the ClinicalTrials portal.